viral
neonat
paediatr
infect
characteris
great
heterogen
clinic
manifest
consid
major
caus
neonat
paediatr
morbid
mortal
almost
year
ago
paediatr
virolog
consid
isol
disciplin
includ
paediatr
infecti
diseas
section
scientif
field
paediatr
howev
past
two
decad
new
advanc
field
clinic
virolog
molecular
medicin
expand
level
knowledg
prevent
diagnosi
treatment
viral
infect
occur
infanc
childhood
develop
chang
highlight
demand
undergradu
postgradu
medic
educ
paediatr
virolog
combin
paediatr
virolog
epidemiolog
molecular
medicin
evidencebas
medicin
clinic
govern
qualiti
improv
pharmacolog
immunolog
workshop
paediatr
virolog
entitl
paediatr
virolog
interact
basic
scienc
clinic
practic
held
octob
athen
greec
offici
session
world
congress
advanc
oncolog
intern
symposium
molecular
medicin
aim
bring
togeth
virologist
paediatr
health
profession
encourag
collabor
intern
network
promot
paediatr
health
moreov
workshop
nobelist
laureat
professor
harald
zur
hausen
emeritu
professor
virolog
univers
freiburg
germani
receiv
nobel
prize
physiolog
medicin
discoveri
human
papilloma
virus
hpv
caus
cervic
cancer
professor
ann
greenough
professor
neonatolog
clinic
respiratori
physiolog
king
colleg
london
uk
vice
presid
scienc
research
royal
colleg
paediatr
child
health
rcpch
honour
paediatr
virolog
studi
group
pvsg
indisput
academ
research
publish
contribut
paediatr
virolog
present
review
provid
overview
wealth
new
materi
differ
area
neonat
paediatr
viral
infect
present
discuss
workshop
interestingli
top
key
messag
tabl
meet
well
statement
nobelist
laureat
professor
harald
zur
hausen
occas
workshop
tabl
ii
includ
recommend
specif
prevent
strategi
viral
infect
along
signific
role
human
breast
milk
respiratori
syncyti
viru
rsv
prophylaxi
issu
includ
necess
vaccin
polici
relat
migrat
crisi
prevent
hepat
newborn
recent
advanc
influenza
vaccin
male
vaccin
hpv
prevent
role
probiot
manag
viral
infect
children
number
differ
infect
occur
earli
period
life
sever
infect
viral
eg
herpesgroup
virus
polyomavirus
torqu
teno
virus
result
longtim
persist
latenc
within
human
specif
cell
type
fate
latent
genom
seem
vari
substanti
may
remain
dormant
whole
lifetim
without
recognis
side
effect
prolong
latenc
genom
may
becom
defect
eventu
degrad
particular
herpesgroup
virus
may
becom
reactiv
lead
local
viral
product
cell
lysi
interact
latent
genom
mutagen
chemic
physic
biolog
factor
may
dysregul
control
latenc
persist
may
thu
result
local
exacerb
mainli
result
immunoreact
prolong
human
breast
feed
month
document
benefici
effect
avoid
viral
infect
eg
noroviru
rotavirusrel
infect
potenti
lethal
newborn
babi
also
shown
reduc
risk
develop
certain
malign
tumour
aris
earli
childhood
eg
acut
lymphoblast
leukemia
young
adolesc
eg
hodgkin
diseas
hd
appar
specif
sugar
human
milk
modifi
receptor
block
uptak
norovirus
rotavirus
breast
feed
phase
matur
immun
system
period
subsequ
facilit
effect
immun
respons
wean
period
uptak
specif
sialic
acid
produc
human
present
cow
milk
meat
product
begin
wean
time
result
incorpor
cell
surfac
glycoprotein
gangliosid
result
modif
cell
surfac
receptor
alter
suscept
specif
viral
infect
eg
human
polyomaviru
type
other
current
analys
suggest
receptor
permit
bind
infecti
agent
present
dairi
cattl
serum
milk
product
lead
longtim
persist
latenc
potenti
pathogen
condit
reactiv
thu
protect
effect
breast
feed
allow
matur
immun
respons
first
year
life
emerg
critic
period
determin
uptak
latenc
specif
infect
chronic
respiratori
morbid
common
prematur
born
infant
multifactori
aetiolog
lower
respiratori
tract
infect
lrti
caus
rsv
increas
morbid
although
prematur
born
infant
function
genet
predispos
rsv
lrti
lung
function
infanc
wors
lrti
rsv
lrti
longterm
effect
evidenc
prematur
born
infant
bronchopulmonari
dysplasia
bpd
subsequ
suffer
rsv
lrti
hospitalis
first
year
birth
infant
need
increas
healthcar
utilis
poorer
pulmonari
function
school
age
limit
data
suggest
rhinoviru
rv
may
advers
affect
respiratoryrel
outcom
prematur
born
infant
previou
studi
prematur
born
infant
bpd
develop
rv
lrti
associ
sustain
worsen
clinic
statu
requir
addit
novel
therapi
prolong
period
time
furthermor
anoth
studi
prematur
born
infant
develop
rv
lrti
infanc
higher
healthcar
utilis
cost
includ
greater
number
hospit
outpati
respiratoryrel
gener
practition
gp
attend
infant
without
viral
lrti
ongo
research
king
colleg
london
uk
recent
reexamin
prematur
born
cohort
school
age
year
data
respiratori
viral
infect
infanc
well
whether
hospit
admiss
requir
record
rv
group
poorer
lung
function
suffer
lrti
infanc
cluster
analysi
data
demonstr
infant
extrem
low
birthweight
requir
prolong
ventil
increas
risk
suffer
rv
lrti
infanc
higher
healthcar
utilis
impair
lung
function
school
age
data
suggest
rsv
rv
lrti
increas
chronic
respiratori
morbid
prematur
born
infant
consequ
taken
consider
regard
develop
relev
prevent
strategi
past
year
greec
one
princip
gateway
countri
european
union
eu
experienc
increas
inflow
refuge
migrant
arriv
sea
greek
island
dodecanes
island
lesbo
samo
agathonisi
end
individu
total
arriv
countri
januari
novemb
correspond
number
report
intern
organ
migrat
iom
individu
major
individu
arriv
greec
came
syria
approxim
follow
afghanistan
iraq
pakistan
algeria
follow
implement
euturkey
agreement
closur
northern
border
greec
march
refuge
migrant
remain
strand
countri
children
worth
note
date
sever
studi
highlight
lower
immunis
coverag
among
refuge
migrant
compar
europeanborn
individu
attribut
low
vaccin
coverag
countri
origin
due
collaps
inadequaci
healthcar
system
sever
problem
also
limit
access
refuge
migrant
vaccin
europ
lack
inform
regard
immunis
statu
financi
problem
host
countri
lack
collabor
among
public
health
author
european
countri
accord
world
health
organ
high
vaccin
coverag
requir
protect
refuge
migrant
asylum
seeker
well
popul
host
countri
ensur
appropri
vaccin
extend
routin
immunis
schedul
individu
move
irrespect
legal
statu
greec
imper
need
emerg
implement
supplementari
immunis
activ
particularli
refuge
children
live
point
care
countri
vaccin
conduct
form
mass
campaign
nongovernment
organis
ngo
signific
experi
expertis
conduct
campaign
san
msf
red
cross
doctor
world
coordin
gener
secretariat
public
health
hellen
ministri
health
framework
recommend
refuge
migrant
vaccin
nation
immunis
committe
follow
vaccin
given
accord
data
collect
ministri
health
work
group
coordin
refugeesmigr
vaccin
may
januari
children
vaccin
infecti
vaccineprevent
diseas
viral
infect
estim
coverag
swoop
among
children
appropri
age
vaccin
measl
mump
rubella
mmr
diphtheria
tetanu
pertussi
poliomyel
pertussi
pneumococc
diseas
haemophilu
influenza
type
b
hepat
b
take
account
difficulti
includ
vaccin
suppli
abovement
result
realli
encourag
fact
import
great
number
immunis
refuge
children
regularli
attend
lesson
greek
school
public
health
author
ngo
inde
work
hard
togeth
order
protect
children
live
one
biggest
crisi
time
infecti
diseas
challeng
today
continu
immunis
refuge
migrant
greec
part
routin
primari
healthcar
develop
plan
provid
immunis
newlyarriv
refuge
migrant
reason
effect
strategi
tailor
immunis
servic
specif
need
target
popul
chronic
infect
hepat
b
viru
hbv
hepat
c
viru
hcv
respons
hepat
mortal
global
estim
million
individu
infect
hbv
anoth
million
hcv
infant
infect
hbv
birth
becom
chronic
carrier
mothertochild
transmiss
mtct
respons
chronic
hbv
infect
develop
sever
liver
diseas
includ
hepatocellular
carcinoma
hcc
cirrhosi
compar
horizont
transmiss
mtct
increas
risk
develop
hcc
mtct
hbv
occur
mostli
birth
rare
utero
postnat
risk
increas
hbeagposit
mother
compar
hbeagneg
mother
also
geograph
differ
risk
mtct
hbv
higher
asia
africa
mtct
hcv
occur
rate
major
caus
paediatr
hcv
infect
prevent
mtct
hbv
hcv
one
synergist
measur
adopt
member
state
commit
toward
elimin
viral
hepat
public
health
threat
prevent
mtct
hbv
achiev
case
deliv
birth
dose
hbv
vaccin
within
h
birth
risk
mtct
hbv
highest
infant
born
younger
mother
hbeagposit
high
viral
load
vaccin
dose
also
risk
factor
mtct
hbv
test
pregnant
women
hbsag
treat
posit
deliveri
administ
birth
dose
hepat
b
immunoglobulin
hbig
infant
birth
success
prevent
mtct
hbv
rate
mtct
hbv
reduc
caesarian
section
deliveri
breast
feed
pose
risk
factor
mtct
hbv
contrast
neither
mode
deliveri
type
feed
shown
risk
factor
mtct
case
hcv
hiv
coinfect
doubl
risk
mtct
hcv
although
high
hcv
viral
load
risk
factor
mtct
current
prevent
risk
factor
direct
act
antivir
daa
approv
pregnanc
univers
screen
hcv
shown
effect
risk
factorbas
screen
prevent
mtct
approv
daa
pregnant
women
children
open
new
horizon
prevent
mtct
hcv
interrupt
mtct
hbv
hcv
intervent
contribut
elimin
viral
hepat
public
health
threat
avert
high
morbid
mortal
sever
liver
diseas
associ
viral
infect
hpv
small
nonenvelop
doublestrand
circular
dna
virus
belong
famili
papillomavirida
hpv
infect
epitheli
tissu
life
cycl
close
intertwin
differenti
epithelium
hpv
requir
host
dna
replic
machineri
order
replic
genom
maintain
keratinocyt
prolif
state
via
action
specif
hpv
protein
best
characteris
thu
creat
environ
amen
carcinogenesi
hpv
known
aetiolog
agent
cervic
cancer
signific
proport
anogenit
cancer
anal
cancer
vagin
vulvar
cancer
penil
cancer
recent
becom
appar
hpv
also
driver
subset
head
neck
squamou
cell
carcinoma
case
particular
tonsillar
base
tongu
carcinoma
addit
hpv
associ
number
benign
neoplasm
includ
common
cutan
wart
genit
wart
oral
papilloma
recurr
respiratori
papillomatosi
rrp
type
hpv
discov
date
primarili
classifi
either
low
highrisk
accord
malign
potenti
mucos
cutan
type
foremost
highrisk
type
isol
cervic
anogenit
head
neck
carcinoma
paediatr
manifest
hpv
infect
includ
skin
wart
oral
papilloma
rrp
anogenit
wart
addit
asymptomat
infect
oral
tonsillar
mucosa
well
genit
mucosa
children
describ
studi
hpv
seroposit
young
children
indic
rel
low
preval
hpv
antibodi
approxim
seropreval
significantli
increas
adolesc
commenc
sexual
activ
mucos
hpv
infect
often
describ
sexual
transmit
infect
howev
presenc
infect
infant
young
children
suggest
viru
may
also
vertic
horizont
transmit
strong
evid
matern
hpv
cervic
infect
time
deliveri
transmit
newborn
strong
associ
develop
juvenil
rrp
presenc
matern
genit
wart
pregnanc
detect
hpv
dna
spermatozoa
semin
plasma
well
amniot
fluid
placent
tissu
suggest
periconceptu
prenat
transmiss
may
also
possibl
hpv
transmit
horizont
ie
kiss
touch
differ
site
autoinocul
case
anogenit
wart
particular
sexual
abus
remain
import
consider
lack
data
persist
hpv
infect
children
relat
subsequ
develop
hpvassoci
diseas
oropharyng
carcinoma
routin
vaccin
girl
age
year
introduc
mani
countri
reduc
incid
anogenit
cancer
nobelist
laureat
professor
harald
zur
hausen
activ
advoc
vaccin
boy
erad
hpv
infect
emphasis
male
hpv
vaccin
includ
current
vaccin
programm
public
professor
karin
michel
harvard
medic
school
entitl
hpv
vaccin
publish
lancet
one
first
public
advoc
vaccin
boy
date
unit
state
canada
australia
austria
current
implement
routin
vaccin
girl
well
boy
recent
guidelin
recommend
vaccin
girl
age
year
primari
target
popul
vaccin
addit
target
popul
femal
year
older
male
feasibl
afford
costeffect
genderneutr
vaccin
may
achiev
greater
herd
protect
effect
direct
protect
male
howev
genderneutr
programm
implement
recent
impact
hpvrelat
diseas
popul
level
remain
determin
nevertheless
strong
data
quadrival
hpv
vaccin
effect
reduc
anal
intraepitheli
neoplasia
reduct
intentiontotreat
popul
perprotocol
popul
similar
prospect
data
penil
cancer
oropharyng
cancer
lack
howev
data
suggest
hpv
infect
site
reduc
follow
vaccin
nonvaccin
children
continu
affect
paediatr
hpvassoci
diseas
vaccin
children
hpv
type
cover
vaccin
increas
vaccin
coverag
may
reduc
hpv
preval
anogenit
infect
also
oral
infect
howev
vaccin
programm
continu
face
challeng
part
due
parent
fear
regard
vaccin
safeti
larg
populationbas
studi
confirm
vaccin
safeti
educ
effort
regard
import
hpv
vaccin
vaccin
efficaci
safeti
profil
necessari
achiev
higher
vaccin
coverag
liveattenu
influenza
vaccin
laiv
use
certain
european
countri
uk
finland
usa
canada
decad
addit
effici
mode
introduct
nasal
spray
randomis
clinic
trial
shown
provid
better
protect
efficaci
inactiv
influenza
vaccin
iiv
children
consid
main
driver
influenza
transmiss
howev
recent
observ
studi
shown
conflict
evid
regard
effect
laiv
influenza
season
reduc
vaccin
effect
observ
unit
state
reason
center
diseas
prevent
control
cdc
recommend
use
iiv
recombin
influenza
vaccin
riv
instead
laiv
season
howev
uk
finland
canada
laiv
shown
protect
drift
influenza
b
virus
suboptim
effect
compar
iiv
studi
attribut
reduc
effect
thermal
instabl
viru
compon
handl
condit
vaccin
certain
perform
limit
one
previou
influenza
vaccin
may
modifi
immun
respons
repeat
vaccin
studi
warrant
determin
reason
reduc
recent
systemat
literatur
review
find
evid
decreas
efficaci
laiv
administ
two
consecut
season
hand
find
studi
evalu
impact
repeat
vaccin
among
health
care
worker
suggest
decreas
serolog
respons
among
highli
vaccin
group
anoth
consortium
season
influenza
vaccin
effect
ii
sive
ii
current
evalu
safeti
effect
laiv
programm
children
vaccin
healthi
children
potenti
provid
direct
protect
children
also
indirect
protect
vulner
group
gener
popul
studi
larg
sampl
size
greater
number
peopl
group
group
repeat
vaccin
requir
populationbas
nation
health
registri
also
valuabl
gener
routin
data
measur
vaccin
impact
time
manner
laiv
use
shown
benefici
past
year
continu
enhanc
surveil
studi
result
requir
order
better
understand
usa
find
possibl
implic
vaccin
polici
europ
worldwid
probiot
eg
lactobacilli
bifidobacteria
saccharomyc
live
microorgan
confer
benefici
health
effect
host
consum
adequ
amount
nonpathogen
normal
host
resist
process
abl
surviv
human
digest
tract
prebiot
eg
fructo
galactooligosaccharid
nonviabl
food
compon
confer
signific
health
benefit
host
modul
intestin
microflora
synbiot
combin
pro
prebiot
gut
microflora
complex
ecosystem
support
structur
function
intestin
mucosa
probiot
abil
modifi
gut
microflora
either
lower
colon
ph
product
shortchain
fatti
acid
scfa
produc
antimicrobi
compound
antitoxin
compet
bacteria
nutrient
also
enhanc
gut
barrier
function
play
role
immunomodul
probiot
use
manag
children
acut
viral
diarrhoea
adjunct
rehydr
therapi
date
paediatr
metaanalys
shown
probiot
reduc
durat
diarrhoea
rang
h
h
well
risk
diarrhoea
last
day
subgroup
rotavirusassoci
diarrhoea
seem
respons
probiot
lactobacillu
rhamnosu
gg
lgg
appear
effect
probiot
benefici
effect
probiot
seem
evid
treatment
initi
earli
h
strain
dosedepend
probiot
use
treat
bacteri
diarrhoea
probiot
also
propos
help
prevent
upper
respiratori
tract
infect
urti
howev
intervent
exist
evid
inconsist
recent
systemat
review
randomis
control
trial
rct
suggest
probiot
prophylaxi
reduc
number
children
one
urti
odd
ratio
confid
interv
ci
number
urti
per
personyear
rate
ratio
ci
outcom
inconsist
result
individu
studi
reflect
estim
heterogen
better
understand
effect
differ
probiot
strain
deeper
insight
mechan
action
requir
valid
specif
strain
carri
potenti
modifi
frequenc
sever
urti
gastrointestin
viral
infect
infant
children
fetus
neonat
suscept
wide
varieti
viral
infect
commonli
involv
central
nervou
system
cn
greater
frequenc
adult
infect
cn
common
worldwid
health
problem
childhood
signific
morbid
mortal
children
virus
common
caus
cn
infect
follow
bacteria
less
frequent
fungi
caus
advanc
prenat
perinat
care
togeth
technolog
advent
imag
modal
enabl
time
detect
detail
explor
symptom
sign
neonat
popul
start
fetal
life
although
imag
practic
unabl
set
diagnosi
viral
infect
fetus
neonat
moreov
reveal
pathogen
howev
potenti
accur
suggest
scenario
map
extent
involv
direct
investig
consult
accordingli
addit
may
reveal
complic
viral
infect
may
caus
confus
usual
requir
special
treatment
imag
find
highli
suggest
cn
viral
infect
fetus
neonat
familiar
clinic
cours
rout
transmiss
imag
appear
usual
prove
help
reach
correct
diagnosi
prompt
time
treatment
gener
sequela
intrauterin
infect
reflect
combin
pathogen
stage
fetal
develop
exposur
occur
congenit
infect
occur
second
third
trimest
may
persist
neonat
affect
gener
neurolog
statu
howev
rule
thumb
later
diagnosi
congenit
infect
made
difficult
identifi
agent
addit
imag
find
may
becom
nonspecif
less
conspicu
incomplet
white
matter
myelin
may
interfer
matern
viral
infect
suspect
combin
prenat
ultrasound
fetal
magnet
reson
imag
mri
may
document
extent
tissu
damag
therefor
contribut
treatment
counsel
neonat
head
ultrasound
sometim
comput
tomographi
ct
mainli
mri
fig
may
reveal
sequela
congenit
viral
infect
ie
microcephali
dystroph
periventricular
calcif
brain
atrophi
may
even
suggest
caus
viru
cytomegaloviru
cmv
previous
healthi
neonat
viral
infect
imag
investig
cn
begin
head
ultrasound
imag
investig
requir
mri
modal
choic
even
emerg
set
noncompl
mening
easier
recognis
clinic
howev
sinc
complic
mening
abscess
infarct
venou
thrombosi
extraaxi
empyema
difficult
diagnos
clinic
imag
play
crucial
role
viral
infect
invad
cn
children
spread
peripher
nervou
system
pn
rare
cn
cn
protect
effect
immun
respons
multilay
barrier
howev
virus
enter
cn
effici
via
bloodstream
directli
infect
nerv
innerv
peripher
tissu
result
immunemedi
patholog
viral
infect
cn
often
caus
mening
characteris
high
fever
headach
vomit
photophobia
neck
stiff
enceph
appear
clinic
evid
neurolog
dysfunct
alter
mental
statu
seizur
behavior
chang
focal
neurolog
sign
clinic
manifest
myeliti
characteris
weak
bladder
dysfunct
flaccid
paralysi
reduc
absent
reflex
radicul
characteris
weak
shoot
pain
dysesthesia
diminish
reflex
complex
syndrom
meningoenceph
encephalomyel
virus
affect
differ
site
cn
enterovirus
herp
simplex
viru
mump
viru
muv
respons
case
asept
mening
wherea
herp
simplex
viru
common
caus
enceph
develop
countri
type
herp
virus
epsteinbarr
viru
ebv
cmv
varicellazost
viru
vzv
human
herp
virus
invad
brain
influenc
neurolog
statu
children
addit
virus
tabl
iii
west
nile
viru
wnv
japanes
enceph
viru
tickborn
enceph
viru
western
eastern
equin
enceph
viru
certain
geograph
distribut
differenti
diagnosi
taken
account
case
children
travel
suscept
area
accord
recent
data
paediatr
intens
care
unit
picu
aglaia
kyriak
children
hospit
athen
greec
among
children
cn
infect
admit
picu
past
year
patient
viral
infect
howev
certain
aetiolog
factor
detect
patient
case
influenza
case
enteroviru
case
wherea
patient
suffer
autoimmun
enceph
patient
suspect
cn
infect
undergo
lumbar
punctur
lp
unless
contraind
due
rais
intracrani
pressur
investig
cerebrospin
fluid
csf
includ
total
differenti
white
cell
count
red
cell
count
microscopi
cultur
protein
glucos
lactat
polymeras
chain
reaction
pcr
test
vzv
enterovirus
possibl
pathogen
depend
clinic
featur
neuroimag
ct
scan
prefer
mri
perform
soon
possibl
mri
perform
within
h
admiss
abnorm
approxim
patient
lesion
specif
certain
aetiolog
factor
electroencephalogram
eeg
consid
seizur
suspect
patient
suspect
viral
enceph
start
treatment
acyclovir
pcr
test
posit
hsv
vzv
continu
treatment
least
day
corticosteroid
also
use
although
role
remain
controversi
strong
immunomodulatori
effect
may
facilit
viral
replic
enteroviru
infect
requir
support
care
sever
case
intraven
immunoglobulin
ivig
alon
combin
high
dose
corticosteroid
drug
oseltamivir
ganciclovir
administ
accord
underli
viral
caus
viral
cn
infect
lifethreaten
emerg
support
care
crucial
includ
airway
manag
cardiorespiratori
support
mainten
fluid
electrolyt
balanc
manag
seizur
accord
specif
guidelin
approxim
patient
requir
picu
admiss
overal
mortal
rate
rang
depend
pathogen
age
clinic
laboratori
find
time
present
approxim
survivor
suffer
form
perman
disabl
seizur
learn
problem
motor
deficit
development
delay
much
higher
incid
two
third
patient
hsv
enceph
case
asthma
consid
year
common
chronic
diseas
childhood
role
allergi
develop
inde
signific
risk
factor
also
associ
pathogenesi
asthma
includ
prematur
parent
histori
asthma
reduc
lung
size
function
chronic
lung
diseas
neuromuscular
cardiovascular
diseas
male
sex
low
socioeconom
statu
syndrom
intrauterin
tobacco
smoke
exposur
passiv
smoke
daycar
attend
earli
exposur
pet
well
viral
respiratori
tract
infect
infanc
among
factor
infect
acut
viral
bronchiol
caus
rsv
rv
particular
recognis
one
signific
predict
marker
develop
asthma
later
childhood
young
adulthood
rsv
common
caus
wheez
seem
domin
first
year
infant
life
winter
period
caus
mainli
acut
bronchiol
rv
detect
caus
agent
acut
bronchiol
lower
tract
viral
infect
older
infant
children
remain
clarifi
though
whether
specif
viral
respiratori
infect
play
caus
role
asthmatogenesi
whether
viralinduc
wheez
marker
predispos
individu
subsequ
develop
asthma
well
demonstr
interact
host
factor
viral
respiratori
infect
promot
recurr
virusinduc
wheez
subsequ
develop
asthma
synergist
interact
allergi
virus
explain
via
variou
mechan
interferon
defici
immun
defect
antiinflammatori
respons
airway
hyper
respons
reduc
barrier
function
recent
randomis
trial
highrisk
infant
treatment
palivizumab
otherwis
healthi
preterm
infant
order
avoid
seriou
rsv
infect
associ
decreas
recurr
wheez
rate
compar
placebo
group
rsv
caus
cytopath
damag
airway
epithelium
affect
function
epithelium
airway
smooth
muscl
date
increas
evid
indic
rv
frequent
caus
common
cold
children
replic
lower
respiratori
tract
caus
exacerb
asthma
certain
featur
infect
rv
includ
stimul
interleukin
il
eotaxin
product
immigr
inflammatori
cell
eosinophil
macrophag
neutrophil
subsequ
increas
factor
consid
import
airway
remodel
vascular
endotheli
growth
factor
point
likelihood
rv
infect
asthmatogen
given
burden
asthma
utmost
import
futur
scientif
attempt
reveal
detail
causal
viral
infect
asthmatogenesi
thu
better
asthmapredict
indic
develop
effect
strategi
asthma
prevent
schedul
includ
research
effect
vaccin
american
excav
agora
athen
well
excav
found
contain
minimum
infant
fetal
skeleton
although
excav
year
ago
detail
content
never
publish
estim
long
bone
length
age
infant
rang
week
utero
month
postterm
peak
week
caus
death
infant
agora
well
topic
much
specul
past
year
suggest
includ
warrel
famin
epidem
diseas
human
sacrific
largescal
infanticid
one
goal
project
evalu
evid
patholog
infant
order
evalu
caus
death
infant
death
rate
natur
caus
ancient
world
high
neonat
may
die
earli
postnat
period
addit
approxim
skeleton
infant
born
preterm
young
week
utero
mani
probabl
either
stillborn
die
complic
associ
prematur
includ
respiratori
distress
problem
thermoregul
cranial
bone
provid
evid
patholog
possibl
infecti
caus
death
lesion
diffus
area
new
bone
form
endocrani
surfac
cruciat
emin
occipit
bone
common
locat
endocrani
reactiv
bone
infant
correspond
find
ancient
modern
skelet
collect
lesion
also
identifi
pariet
frontal
bone
often
area
venou
drainag
greater
wing
bodi
sphenoid
bone
also
exhibit
endocrani
prolif
bone
lesion
found
lesion
extend
beyond
cruciat
emin
occipit
haironend
lesion
like
patholog
rather
indic
normal
bone
growth
occipit
squama
collect
exhibit
clear
patholog
bone
deposit
infect
birthrel
trauma
thought
caus
lesion
infect
mening
thought
activ
periost
membran
result
new
bone
deposit
exact
mechan
clear
infecti
pathogen
commonli
introduc
cut
umbil
cord
cultur
dietari
practic
like
infant
ancient
athen
suffer
array
viral
infect
modern
infant
prone
includ
hsv
influenza
viru
corona
viru
enteroviru
ebv
arboviru
perinat
period
ancient
athen
peril
consider
risk
viral
bacteri
infect
skeleton
well
provid
brief
glimps
short
live
earli
death
youngest
athenian
provid
optim
care
paediatr
patient
paediatrician
commit
lifelong
learn
follow
quot
athenian
solon
bc
one
seven
wise
men
ancient
greec
grow
old
learn
someth
new
everi
day
date
import
continu
medic
educ
cme
also
known
continu
medic
develop
cmd
recognis
method
improv
qualiti
paediatr
care
sever
paediatr
organis
institut
european
academi
paediatr
rcpch
profession
respons
practic
paediatrician
maintain
develop
increas
knowledg
clinic
skill
profession
perform
aim
enhanc
clinic
effect
compet
paediatr
virolog
inde
new
educ
challeng
rapidli
increas
chang
educ
need
prefer
foster
sever
develop
field
clinic
virolog
molecular
medicin
emerg
viral
diseas
well
technic
innov
expand
diagnost
therapeut
approach
toward
neonat
paediatr
viral
infect
feedback
receiv
particip
workshop
paediatr
virolog
held
respect
athen
highlight
need
cme
cme
paediatr
virolog
must
emphasis
acquisit
knowledg
also
instruct
paediatrician
process
decis
make
selfdirect
learn
activ
encourag
howev
cme
paediatr
virolog
also
instil
collegi
interact
collabor
disciplin
without
doubt
paediatr
virologist
lead
role
cme
paediatr
virolog
focus
academ
excel
stateoftheart
medic
educ
practic
paediatrician
discuss
requir
differ
educ
activ
onlin
learn
interact
casebas
workshop
creation
educ
eplatform
increas
potenti
worth
promot
peadiatr
public
health
